Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

549.65 -19.47 (-3.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio? 
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
14 Analysts Have This To Say About argenx
Via Benzinga
Argenx Shares Drop After Q1 Miss, But Retail Traders Call Sub-$550 ‘An Absolute Steal’
Despite the Q1 miss, management reiterated confidence in its long-term “Vision 2030” strategy, highlighting strong Vyvgart uptake in gMG and CIDP and the recent U.S. approval of a self-injection... 
Via Stocktwits
Topics Earnings
Exposures Financial
Earnings Scheduled For May 8, 2025
Via Benzinga
A Look Into argenx Inc's Price Over Earnings
Via Benzinga
P/E Ratio Insights for argenx
Via Benzinga
What's Driving the Market Sentiment Around argenx?
Via Benzinga
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble
The company's drug treats two autoimmune conditions and recently launched with a prefilled synringe for at-home treatment. 
Via Investor's Business Daily
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx to Present at BofA Securities 2025 Health Care Conference
From argenx SE
Via GlobeNewswire
P/E Ratio Insights for argenx
Via Benzinga
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
From argenx SE
Via GlobeNewswire
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From argenx SE
Via GlobeNewswire
Does ARGENX SE - ADR (NASDAQ:ARGX) meet the Minervini criteria?
A fundamental and technical analysis of (NASDAQ:ARGX): Is ARGENX SE - ADR (NASDAQ:ARGX) suited for high growth investing? 
Via Chartmill
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options. 
Via Benzinga
Exposures Product Safety
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
From argenx SE
Via GlobeNewswire
Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug
The prefilled syringe will cost 4% more than the under-the-skin shot. 
Via Investor's Business Daily
Exposures Product Safety
What 11 Analyst Ratings Have To Say About argenx
Via Benzinga
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients
Argenx reports long-term Vyvgart data showing lasting efficacy in gMG and CIDP, with strong safety and symptom control across multiple studies. 
Via Benzinga
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
From argenx SE
Via GlobeNewswire
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
Looking Into argenx's Recent Short Interest
Via Benzinga
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback